Devices & Diagnostics

$125M early stage fund seeks to invest in health startups in N.C. and southeastern U.S.

Hatteras Venture Partners announced Monday that the company has closed its fourth fund totaling $125 million. The Durham, North Carolina-based venture capital firm invests in device, diagnostic, biopharma, health IT and human-health related startups primarily based in North Carolina and the southeastern U.S. The HVP IV fund also established a HVP IV SBIC, which is the […]

Hatteras Venture Partners announced Monday that the company has closed its fourth fund totaling $125 million.

The Durham, North Carolina-based venture capital firm invests in device, diagnostic, biopharma, health IT and human-health related startups primarily based in North Carolina and the southeastern U.S.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

The HVP IV fund also established a HVP IV SBIC, which is the first licensee of the U.S. Small Business Administration’s (SBA) newly established Early Stage SBIC Program.

An earlier, initial closing of the HPV IV fund in 2011 led to the establishment of the Hatteras Discovery, a sub-allocation of the fourth fund, to invest in seed-stage startups. Hatteras Discovery has already invested in Clearside BiomedicalCoferon and G1 Therapeutics. The larger HPV IV fund has invested in Clinverse Inc. and co-invested with Hatteras Discovery in Clearside and Coferon.

“We are gratified to achieve our fund target of $125 million,” said Bob Ingram, general partner in a news release. “These funds will allow us to drive the numerous seed and early stage opportunities we are identifying in the human medicine life science field.  During our fundraising process, our deal flow has grown substantially in number and quality.”

Founded in 2000, Hatteras has more than $250 million under management.